Bristol-Myers Squibb and AstraZeneca Purchase Amylin
publication date: Jul 2, 2012
The two pharmaceutical companies will collaborate to commercialize the diabetes portfolio of Amylin. We think the deal is value neutral.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.